Aripiprazole pharmaceutical co-crystal and preparation method thereof
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
An aripiprazole and drug technology, applied in the field of aripiprazole drug co-crystal and preparation thereof, can solve the problems of adverse reactions, poor solubility of aripiprazole, etc., and achieve the advantages of reducing solubility and muscle irritation. Effect
Active Publication Date: 2021-07-13
JIANGSU OCEAN UNIV
View PDF3 Cites 3 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
Aripiprazole has a better clinical effect, but there are also application defects. When it is used at a normal therapeutic dose, a series of adverse reactions will occur, such as head
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
preparation example Construction
[0019] The preparation method of aripiprazole drug co-crystal, the method is a grinding method, which specifically includes the following steps: putting aripiprazole and resveratrol into a mortar for grinding in equimolar amounts, and adding a ketone or alkyl nitrile solvent before grinding , manual grinding for 30min, in Vacuum-dried to obtain the drug co-crystal of aripiprazole.
[0020] The mass ratio of aripiprazole to resveratrol is 1:1. The co-crystal of aripiprazole and resveratrol is used in the preparation of various antipsychotic drugs, and the schizophrenia includes positive symptoms, negative symptoms, cognitive impairment and bipolar disorder.
[0021] The instrument that detects drug eutectic structure and performance among the present invention is as follows:
[0022] 1. X-ray powder diffractometer, produced by PANalytical Company in the Netherlands, model X’Pert PRO MPD, Cu-K(α), tube voltage 40kV, tube current 40mA, scanning speed 2° / min;
[0023] 2. Diffe...
Embodiment 1
[0027] Accurately weigh 224 mg (0.5 mmol) of aripiprazole and 114 mg (0.5 mmol) of resveratrol, place them in a mortar, add acetonitrile dropwise and grind for 30 min to obtain a white powder, dry in vacuum at 50°C for 4 h, and collect the solid, namely It is the co-crystal of aripiprazole and resveratrol (ARI-RSV).
Embodiment 2
[0029] Accurately weigh 224mg (0.5mmol) of aripiprazole and 114mg (0.5mmol) of resveratrol, put them in a mortar, add methyl isobutyl ketone dropwise and grind for 30min to obtain a white powder, and dry in vacuum at 50°C for 4h , to collect the solid, which is the co-crystal of aripiprazole and resveratrol (ARI-RSV).
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
The invention discloses an aripiprazole pharmaceutical co-crystal and a preparation method thereof. The aripiprazole pharmaceutical co-crystal is formed through intermolecular hydrogen bonds by taking aripiprazole as an active pharmaceutical ingredient and resveratrol as a precursor. The preparation method of the aripiprazole pharmaceutical co-crystal comprises the following steps: grinding aripiprazole and resveratrol in a mortar with equal mole, adding a ketone or alkyl nitrile solvent before grinding, manually grinding for 30 minutes, and drying in vacuum to obtain the aripiprazole pharmaceutical co-crystal. A powder dissolution experiment of aripiprazole and resveratrol shows that the dissolution rate of aripiprazole is slowed down in an acetic acid buffer solution with the pH value of 4.0 and a phosphoric acid buffer solution with the pH value of 6.8, and a potential slow release effect is shown, so that the muscle injection prepared from the aripiprazole eutectic crystal can be used for treating schizophrenia in a long-acting manner, can be used for preventing and treating the schizophrenia, and reduces the muscle irritation.
Description
technical field [0001] The invention relates to the field of drug co-crystals, in particular to an aripiprazole drug co-crystal and a preparation method thereof. Background technique [0002] At room temperature, active pharmaceutical ingredients exist in various solid forms, such as polymorphs, solvates, hydrates, co-crystals, amorphous forms, and salts. The efficacy of a drug depends largely on the physical and chemical properties of the drug itself and the selected dosage form, and the different solid forms of the drug have an impact on the solubility, stability, dissolution rate and bioavailability of the drug; drug co-crystals are based on Principles of supramolecular chemistry, that is, molecular recognition and supramolecular self-assembly through intermolecular synergy. The active pharmaceutical ingredient (API) self-assembles with a suitable cocrystal former (CCF) through hydrogen bonds, or non-covalent bonds with saturation and directionality (such as van der Waal...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more